AstraZeneca reports positive results from Phase III trial of exenatide in type 2 diabetes
The trial called DURATION-NEO-1 compared an investigational formulation of exenatide once-weekly suspension for autoinjection with twice-daily exenatide (Byetta) injection in these patients who had inadequate glycaemic control. About
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.